C

Concert Pharmaceuticals Inc
F:73C

Watchlist Manager
Concert Pharmaceuticals Inc
F:73C
Watchlist
Price: 7.818 EUR
Market Cap: 374.8m EUR

Concert Pharmaceuticals Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Concert Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
C
Concert Pharmaceuticals Inc
F:73C
Cash from Operating Activities
-$55.2m
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Concert Pharmaceuticals Inc
Glance View

Market Cap
374.8m EUR
Industry
Biotechnology

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. The company is headquartered in Lexington, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2014-02-13. The firm is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The firm is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The firm is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.

73C Intrinsic Value
Not Available
C

See Also

What is Concert Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-55.2m USD

Based on the financial report for Dec 31, 2021, Concert Pharmaceuticals Inc's Cash from Operating Activities amounts to -55.2m USD.

What is Concert Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-4%

Over the last year, the Cash from Operating Activities growth was 20%. The average annual Cash from Operating Activities growth rates for Concert Pharmaceuticals Inc have been -5% over the past three years , -4% over the past five years .

Back to Top